New drug aims to tame rare blood disorder flares

NCT ID NCT04191304

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This Phase 3 study tests whether benralizumab, a biologic injection given every 4 weeks, can reduce flares in people with hypereosinophilic syndrome (HES), a rare condition where too many eosinophils cause organ damage. About 134 patients aged 12 and older will receive either benralizumab or a placebo for 24 weeks, followed by an open-label extension where everyone gets the drug. The main goal is to see how long it takes for a flare to occur.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: Benralizumab (a biologic drug given as an injection every 4 weeks)
What this could lead to: If it works, this could provide a new treatment option to reduce flares and control symptoms for people with hypereosinophilic syndrome.
What could go wrong: This is a Phase 3 trial, but results are not yet final. The drug may not work better than placebo, and side effects are possible. The study is also relatively small (134 participants).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

134 people

The number who actually took part.

Started

Jul 2020

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Provision of the signed and dated written informed consent of the patient or the patient's legally authorised representative, and informed assent from the patient (per local regulations) prior to any mandatory study-specific procedures, sampling, and analyses 2. Males and females 12 years of age and older at the time of signing the ICF 3. Documented diagnosis of HES (history of persistent eosinophilia \> 1500 cells/μL without secondary cause on 2 examinations \[interval ≥ 1 month; Valent et al 2012\] and evidence of end organ manifestations attributable to the eosinophilia) 4. Documented negative testing for the FIP1L1-PDGFRA fusion tyrosine kinase gene translocation 5. Stable HES treatment dose(s) and regimen for ≥ 4 weeks at the time of Visit 1 6. Signs or symptoms of HES worsening/flare and/or laboratory abnormalities indicative of HES worsening/flare (other than isolated eosinophilia) at Visit 1 OR a documented history of 2 or more HES worsening/flares within 12 months prior to Visit 1 requiring an escalation in therapy a. At least one flare within the past 12 months must not be related to a decrease in HES therapy during the 4 weeks prior to the flare 7. AEC ≥ 1000 cells/μL at Visit 1 (assessed by local laboratory) 8. Corticosteroid responsiveness defined as an AEC \< 1000 cells/μL after a 2-day course of OCS (prednisone/prednisolone) 1 mg/kg/day at Visit 2 (assessed by local laboratory). Other OCSs in equivalent doses are permitted 9. WOCBP must agree to use a highly effective method of birth control (confirmed by the investigator) from enrolment, throughout the study duration, and within 12 weeks after last dose of IP and have a negative urine dipstick pregnancy test result on Visit 1. Highly effective methods of birth control (those that can achieve a failure rate of less than 1% per year when used consistently and correctly) include: 1. Combined (oestrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal 2. Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, or implantable 3. Intrauterine device 4. Intrauterine hormone-releasing system 5. Bilateral tubal occlusion 6. Sexual abstinence, ie, refraining from heterosexual intercourse (the reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient) 7. Vasectomised sexual partner (provided that partner is the sole sexual partner of the WOCBP study patient and that the vasectomised partner has received medical assessment of the surgical success) Exclusion Criteria 1. Life-threatening HES and/or HES complication(s) as judged by the investigator: 1. Medical intervention for HES-related life-threatening event(s) within 12 weeks prior to randomization 2. History of thrombotic complications, stroke, or significant cardiac damage related to HES, if the respective events were life threatening and currently represent a risk of life-threatening disease complications. Events that occurred in the past but considered resolved or stable, can be accepted if, as per investigator's judgment, participation in the study will not put the patient at risk 3. Disease severity that in the opinion of the investigator makes the patient inappropriate for inclusion in the study 2. Presence of FIP1L1-PDGFRA fusion tyrosine kinase gene translocation or other known imatinib-sensitive mutation 3. Definitive diagnosis of eosinophilic granulomatosis with polyangiitis 4. Known, preexisting, clinically significant endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, haematological, respiratory, or any other system abnormalities that are not associated with HES and are uncontrolled with standard treatment which, in the opinion of the investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete the entire duration of the study 5. Hypereosinophilia of unknown significance 6. Cardiovascular: Documented history of any clinically significant cardiac damage, clinically significant echocardiography (if available) or ECG findings within 12 months prior to Visit 1 or clinically significant ECG findings at screening that in the opinion of the investigator may put the patients at risk 7. Known currently active liver disease 1. Chronic stable hepatitis B and C (including positive testing for hepatitis B surface antigen or hepatitis C antibody) or other stable chronic liver disease are acceptable if patient otherwise meets eligibility criteria. Stable chronic liver disease should generally be defined by the absence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, oesophageal or gastric varices, or persistent jaundice, or cirrhosis 2. ALT or AST level ≥ 3 × ULN during the screening period (AST or ALT \> 5 × ULN if documented HES with liver manifestations). Transient increase of AST/ALT level that resolves by the time of randomisation is acceptable if, in the investigator's opinion, the patient does not have an active liver disease and meets other eligibility criteria 8. Current or history of malignancy within 5 years before the screening visit with the following exceptions: 1. Patients treated for in situ carcinoma of the cervix who have completed curative therapy and are in remission for at least 12 months prior to signing the informed consent and 2. Patients with basal cell or superficial squamous skin cancer 3. Patients who have had other malignancies are eligible provided that the patient is in remission and curative therapy was completed at least 5 years prior to the date informed consent was obtained 9. Diagnosis of systemic mastocytosis 10. Chronic or ongoing active infections requiring systemic treatment, as well as clinically significant viral, bacterial, or fungal infection within 4 weeks prior to Visit 1 11. A helminth parasitic infection diagnosed within 24 weeks prior to Visit 1 that has not been treated or has failed to respond to standard of care therapy. A confirmation of a complete resolution of any helminth parasitic infection prior to Visit 1 should be available 12. A history of known immunodeficiency disorder other than that explained by the use of OCS or other therapy taken for HES. Positive HIV test 14\. Evidence of prior benralizumab treatment failure

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypereosinophilic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypereosinophilic syndrome

Contacts and locations

Locations

Research Site

La Jolla, California, 92037, United States
Research Site

Atlanta, Georgia, 30324, United States
Research Site

Bethesda, Maryland, 20892, United States
Research Site

Ann Arbor, Michigan, 48105, United States
Research Site

Durham, North Carolina, 27705, United States
Research Site

Cleveland, Ohio, 44106, United States
Research Site

Columbus, Ohio, 43212, United States
Research Site

Salt Lake City, Utah, 84112, United States
Research Site

Rosario, 2000, Argentina
Research Site

Innsbruck, 6020, Austria
Research Site

Brussels, 1070, Belgium
Research Site

Edegem, 2650, Belgium
Research Site

Chengdu, 610041, China
Research Site

Shanghai, 200040, China
Research Site

Tianjin, 300020, China
Research Site

Xiamen, 361015, China
Research Site

Zhengzhou, 450008, China
Research Site

København Ø, 2100, Denmark
Research Site

Lille, 59037, France
Research Site

Pessac, 33604, France
Research Site

Strasbourg, 67091, France
Research Site

Suresnes, 92151, France
Research Site

Toulouse, 31059, France
Research Site

Hanover, 30625, Germany
Research Site

Kirchheim, 73230, Germany
Research Site

Mannheim, 68167, Germany
Research Site

Ahmedabad, 380013, India
Research Site

Ajmer, 305001, India
Research Site

Delhi, 110029, India
Research Site

Haifa, 34362, Israel
Research Site

Holon, 58100, Israel
Research Site

Jerusalem, 91120, Israel
Research Site

Kfar Saba, 44218, Israel
Research Site

Petah Tikva, 49100, Israel
Research Site

Ramat Gan, 5265601, Israel
Research Site

Rehovot, 76100, Israel
Research Site

Tel Aviv, 64239, Israel
Research Site

Bologna, 40138, Italy
Research Site

Chiba, 260-0852, Japan
Research Site

Hamamatsu, 431-3192, Japan
Research Site

Ichikawa-shi, 272-8516, Japan
Research Site

Kawasaki-shi, 211-8510, Japan
Research Site

Nishinomiya-shi, 663-8501, Japan
Research Site

Osaka, 530-8480, Japan
Research Site

Sendai, 980-8574, Japan
Research Site

Rotterdam, 3015 GD, Netherlands
Research Site

Chęciny, 26-060, Poland
Research Site

Gdansk, 80-214, Poland
Research Site

Lodz, 90-153, Poland
Research Site

Seoul, 5505, South Korea
Research Site

Santander, 39010, Spain
Research Site

London, W2 1NY, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.